Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Kidney Int ; 70(10): 1847-57, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17021608

ABSTRACT

Urinary exosomes containing apical membrane and intracellular fluid are normally secreted into the urine from all nephron segments, and may carry protein markers of renal dysfunction and structural injury. We aimed to discover biomarkers in urinary exosomes to detect acute kidney injury (AKI), which has a high mortality and morbidity. Animals were injected with cisplatin. Urinary exosomes were isolated by differential centrifugation. Protein changes were evaluated by two-dimensional difference in gel electrophoresis and changed proteins were identified by mass spectrometry. The identified candidate biomarkers were validated by Western blotting in individual urine samples from rats subjected to cisplatin injection; bilateral ischemia and reperfusion (I/R); volume depletion; and intensive care unit (ICU) patients with and without AKI. We identified 18 proteins that were increased and nine proteins that were decreased 8 h after cisplatin injection. Most of the candidates could not be validated by Western blotting. However, exosomal Fetuin-A increased 52.5-fold at day 2 (1 day before serum creatinine increase and tubule damage) and remained elevated 51.5-fold at day 5 (peak renal injury) after cisplatin injection. By immunoelectron microscopy and elution studies, Fetuin-A was located inside urinary exosomes. Urinary Fetuin-A was increased 31.6-fold in the early phase (2-8 h) of I/R, but not in prerenal azotemia. Urinary exosomal Fetuin-A also increased in three ICU patients with AKI compared to the patients without AKI. We conclude that (1) proteomic analysis of urinary exosomes can provide biomarker candidates for the diagnosis of AKI and (2) urinary Fetuin-A might be a predictive biomarker of structural renal injury.


Subject(s)
Acute Kidney Injury/urine , Blood Proteins/urine , Proteomics/methods , Reperfusion Injury/urine , Acute Kidney Injury/etiology , Acute Kidney Injury/pathology , Adult , Aged , Aged, 80 and over , Animals , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacology , Biomarkers/urine , Cell Membrane/metabolism , Cisplatin/adverse effects , Cisplatin/pharmacology , Female , Humans , Kidney/drug effects , Kidney/injuries , Kidney/pathology , Male , Middle Aged , Models, Animal , Rats , Reperfusion Injury/etiology , Reperfusion Injury/pathology , alpha-2-HS-Glycoprotein , alpha-Fetoproteins/urine
2.
J Biol Chem ; 275(12): 9070-7, 2000 Mar 24.
Article in English | MEDLINE | ID: mdl-10722758

ABSTRACT

Aquaporin-5 (AQP5) is a water channel protein expressed in lung, salivary gland, and lacrimal gland epithelia. Each of these sites may experience fluctuations in surface liquid osmolarity; however, osmotic regulation of AQP5 expression has not been reported. This study demonstrates that AQP5 is induced by hypertonic stress and that induction requires activation of extracellular signal-regulated kinase (ERK). Incubation of mouse lung epithelial cells (MLE-15) in hypertonic medium produced a dose-dependent increase in AQP5 expression; AQP5 protein peaked by 24 h and returned to baseline levels within hours of returning cells to isotonic medium. AQP5 induction was observed only with relatively impermeable solutes, suggesting an osmotic pressure gradient is required for induction. ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction. AQP5 induction was also observed in the lung, salivary, and lacrimal glands of hyperosmolar rats, suggesting potential physiologic relevance for osmotic regulation of AQP5 expression. This report provides the first example of hypertonic induction of an extrarenal aquaporin, as well as the first association between mitogen-activated protein kinase signaling and aquaporin expression.


Subject(s)
Aquaporins/genetics , MAP Kinase Signaling System , Membrane Proteins , Osmotic Pressure , Animals , Aquaporin 5 , Enzyme Activation , Epithelial Cells/cytology , Epithelial Cells/metabolism , Flavonoids/pharmacology , Gene Expression Regulation , Lacrimal Apparatus/metabolism , Lung/cytology , Lung/metabolism , Male , Mice , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Rats , Rats, Sprague-Dawley , Submandibular Gland/metabolism
3.
J Biol Chem ; 274(26): 18414-20, 1999 Jun 25.
Article in English | MEDLINE | ID: mdl-10373448

ABSTRACT

Binding of vinculin to adhesion plaque proteins is restricted by an intramolecular association of vinculin's head and tail regions. Results of previous work suggest that polyphosphoinositides disrupt this interaction and thereby promote binding of vinculin to both talin and actin. However, data presented here show that phosphatidylinositol 4,5-bisphosphate (PI4,5P2) inhibits the interaction of purified tail domain with F-actin. Upon re-examining the effect of PI4,5P2 on the actin and talin-binding activities of intact vinculin, we find that when the experimental design controls for the effect of magnesium on aggregation of PI4,5P2 micelles, polyphosphoinositides promote interactions with the talin-binding domain, but block interactions of the actin-binding domain. In contrast, if vinculin is trapped in an open confirmation by a peptide specific for the talin-binding domain of vinculin, actin binding is allowed. These results demonstrate that activation of the actin-binding activity of vinculin requires steps other than or in addition to the binding of PI4,5P2.


Subject(s)
Actins/metabolism , Phosphatidylinositol Phosphates/pharmacology , Vinculin/metabolism , Animals , Binding Sites/drug effects , Blotting, Western , Chickens , Magnesium Chloride/pharmacology , Micelles , Phosphatidylinositol 4,5-Diphosphate/administration & dosage , Phosphatidylinositol 4,5-Diphosphate/pharmacology , Talin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...